Structure-dependent binding and activation of perfluorinated compounds on human peroxisome proliferator-activated receptor γ

Toxicology and Applied Pharmacology

Volumn 279, Issue 3, 2014, Pages 275-283

  Zhang, Lianying ^a,b   Ren, Xiao Min ^a   Wan, Bin ^a   Guo, Liang Hong ^a  

^a RESEARCH CENTER FOR ECO ENVIRONMENTAL SCIENCES   (China)

^b DEZHOU UNIVERSITY   (China)

Author keywords

Activation potency; Ligand binding assay; Molecular docking; PAR ; Perfluorinated compounds; Structure dependent

Indexed keywords

ALCOHOL; CARBON; CARBOXYLIC ACID; FUNCTIONAL GROUP; PERFLUORO COMPOUND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; SULFONIC ACID DERIVATIVE; ROSIGLITAZONE;

ARTICLE; BINDING AFFINITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG POTENCY; FATTY ACID METABOLISM; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID METABOLISM; LUCIFERASE ASSAY; MOLECULAR DOCKING; PROTEIN BINDING; PROTEIN STRUCTURE; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION INITIATION; CELL DIFFERENTIATION; DISSOCIATION CONSTANT; ENZYME ACTIVATION; ENZYME BINDING; HYDROGEN BOND; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN PURIFICATION; PROTEIN SECONDARY STRUCTURE;

ACTIVATION POTENCY; LIGAND BINDING ASSAY; MOLECULAR DOCKING; PARΓ; PERFLUORINATED COMPOUNDS; STRUCTURE-DEPENDENT;

BINDING, COMPETITIVE; CARBOXYLIC ACIDS; CELL LINE; CELL SURVIVAL; CELLS, CULTURED; CIRCULAR DICHROISM; COLORING AGENTS; FLUOROCARBONS; HUMANS; MODELS, MOLECULAR; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PPAR GAMMA; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION;

EID: 84907181923     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.06.020     Document Type: Article

References (45)

1. Asami-Miyagishi R., Iseki S., Usui M., Uchida K., Kubo H., Morita I. Expression and function of PPAR gamma in rat placental development. Biochem. Biophys. Res. Commun. 2004, 315:497-501.
2. Barry V., Winquist A., Steenland K. Perfluorooctanoic acid (PFOA) exposures and incident cancers among adults living near a chemical plant. Environ. Health Perspect. 2013, 121:1313-1318.
3. Benninghoff A.D., Bisson W.H., Koch D.C., Ehresman D.J., Kolluri S.K., William D.E. Estrogen-like activity of perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro. Toxicol. Sci. 2011, 120:42-58.
4. Berger J., Wagner J.A. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Diabetes Technol. Ther. 2002, 4:163-174.
5. Berry E.B.E., Eykholt R., Helliwell R.J.A., Gilmour R.S., Mitchell M.D., Marvin K.W. Peroxisome proliferator-activated receptor isoform expression changes in human gestational tissues with labor at term. Mol. Pharmacol. 2003, 64:1586-1590.
6. Bischel H.N., MacManus-Spencer L.A., Luthy R.G. Noncovalent interactions of long-chain perfluoroalkyl acids with serum albumin. Environ. Sci. Technol. 2010, 44:5263-5269.
7. Bjorklund J.A., Thuresson K., De Wit C.A. Perfluoroalkyl compounds (PFCs) in indoor dust: concentrations, human exposure estimates, and sources. Environ. Sci. Technol. 2009, 43:2276-2281.
8. Bruning J.B., Chalmers M.J., Prasad S., Busby S.A., Karnenecka T.M., He Y., Nettles K.W., Griffin P.R. Partial agonists activate PPAR gamma using a helix 12 independent mechanism. Structure 2007, 15:1258-1271.
9. Buhrke T., Kibellus A., Lampen A. In vitro toxicological characterization of perfluorinated carboxylic acids with different carbon chain lengths. Toxicol. Lett. 2013, 218:97-104.
10. Conder J.M., Hoke R.A., De Wolf W., Russell M.H., Buck R.C. Are PFCAs bioaccumulative? A critical review and comparison with regulatory lipophilic compounds. Environ. Sci. Technol. 2008, 42(4):995-1003.
11. Corsini E., Sangiovanni E., Avogadro A., Galbiati V., Viviani B., Marinovich M., Galli C.L., Dell'Agli M., Germolec D.R. In vitro characterization of the immunotoxic potential of several perfluorinated compounds (PFCs). Toxicol. Appl. Pharmacol. 2012, 258:248-255.
12. Cronet P., Petersen J.F.W., Folmer R., Blomberg N., Sjoblom K., Karlsson U., Lindstedt E.L., Bamberg K. Structure of the PPAR alpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9:699-706.
13. Elcombe C.R., Elcombe B.M., Foster J.R., Chang S.-C., Ehresman D.J., Butenhoff J.L. Hepatocellular hypertrophy and cell proliferation in Sprague-Dawley rats from dietary exposure to potassium perfluorooctanesulfonate results from increased expression of xenosensor nuclear receptors PPAR alpha and CAR/PXR. Toxicology 2012, 293:16-29.
14. Gao Y., Li X., Guo L.-H. Assessment of estrogenic activity of perfluoroalkyl acids based on ligand-induced conformation state of human estrogen receptor. Environ. Sci. Technol. 2013, 47:634-641.
15. Giesy J.P., Kannan K. Perfluorochemical surfactants in the environment. Environ. Sci. Technol. 2002, 36:146A-152A.
16. Houde M., Martin J.W., Letcher R.J., Solomon K.R., Muir D.C.G. Biological monitoring of polyfluoroalkyl substances: a review. Environ. Sci. Technol. 2006, 40:3463-3473.
17. Ibrahim W.N.W., Tofighi R., Onishchenko N., Rebellato P., Bose R., Uhlen P., Ceccatelli S. Perfluorooctane sulfonate induces neuronal and oligodendrocytic differentiation in neural stem cells and alters the expression of PPAR gamma in vitro and in vivo. Toxicol. Appl. Pharmacol. 2013, 269:51-60.
18. Kennedy G.L., Butenhoff J.L., Olsen G.W., O'Connor J.C., Seacat A.M., Perkins R.G., Biegel L.B., Murphy S.R., Farrar D.G. The toxicology of perfluorooctanoate. Crit. Rev. Toxicol. 2004, 34:351-384.
19. Kleszczynski K., Gardzielewski P., Mulkiewicz E., Stepnowski P., Skladanowski A.C. Analysis of structure-cytotoxicity in vitro relationship (SAR) for perfluorinated carboxylic acids. Toxicol. In Vitro 2007, 21:1206-1211.
20. Krafft M.P., Riess J.G. Chemistry, physical chemistry, and uses of molecular fluorocarbon-hydrocarbon diblocks, triblocks, and related compounds-unique "Apblar" components for self-assembled colloid and interface engineering. Chem. Rev. 2009, 109:1714-1792.
21. Lea W.A., Simeonov A. Fluorescence polarization assays in small molecule screening. Expert Opin. Drug Discov. 2011, 6:17-32.
22. Liberato M.V., Nascimento A.S., Ayers S.D., Lin J.Z., Cvoro A., Silveira R.L., Martinez L., Souza P.C.T., Saidemberg D., Deng T., Amato A.A., Togashi M., Hsueh W.A., Phillips K., Palma M.S., Neves F.A.R., Skaf M.S., Webb P., Polikarpov I. Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) gamma activators and pan-ppar partial agonists. PLoS One 2012, 7(5):e36297.
23. Lind L., Zethelius B., Salihovic S., van Bavel B., Lind P.M. Circulating levels of perfluoroalkyl substances and prevalent diabetes in the elderly. Diabetologia 2014, 57:473-479.
24. Malapaka R.R.V., Khoo S., Zhang J., Choi J.H., Zhou X.E., Xu Y., Gong Y., Li J., Yong E.-L., Chalmers M.J., Chang L., Resau J.H., Griffin P.R., Chen Y.E., Xu H.E. Identification and mechanism of 10-carbon fatty acid as modulating ligand of peroxisome proliferator-activated receptors. J. Biol. Chem. 2012, 287:183-195.
25. Maloney E.K., Waxman D.J. Trans-activation of PPAR alpha and PPAR gamma by structurally diverse environmental chemicals. Toxicol. Appl. Pharmacol. 1999, 161:209-218.
26. Minata M., Harada K.H., Karrman A., Hitomi T., Hirosawa M., Murata M., Gonzalez F.J., Koizumi A. Role of peroxisome proliferator-activated receptor-alpha in hepatobiliary injury induced by ammonium perfluorooctanoate in mouse liver. Ind. Health 2010, 48:96-107.
27. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395:137-143.
28. Palmer C.N.A., Wolf C.R. Cis-parinaric acid is a ligand for the human peroxisome proliferator activated receptor gamma: development of a novel spectrophotometric assay for the discovery of PPAR gamma ligands. FEBS Lett. 1998, 431:476-480.
29. Peden-Adams M.M., Keller J.M., EuDaly J.G., Berger J., Gilkeson G.S., Keil D.E. Suppression of humoral immunity in mice following exposure to perfluorooctane sulfonate. Toxicol. Sci. 2008, 104:144-154.
30. Prevedouros K., Cousins I.T., Buck R.C., Korzeniowski S.H. Sources, fate and transport of perfluorocarboxylates. Environ. Sci. Technol. 2006, 40:32-44.
31. Raymer J.H., Michael L.C., Studabaker W.B., Olsen G.W., Sloan C.S., Wilcosky T., Walmer D.K. Concentrations of perfluorooctane sulfonate (PFOS) and perfluorooctanoate (PFOA) and their associations with human semen quality measurements. Reprod. Toxicol. 2012, 33:419-427.
32. Schade S.Z., Jolley M.E., Sarauer B.J., Simonson L.G. BODIPY-alpha-casein, a pH-independent protein substrate for protease assays using fluorescence polarization. Anal. Biochem. 1996, 243:1-7.
33. Takacs M.L., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. Toxicol. Sci. 2007, 95:108-117.
34. Tsukahara T., Tsukahara R., Yasuda S., Makarova N., Valentine W.J., Allison P., Yuan H.B., Baker D.L., Li Z.G., Bittman R., Parrill A., Tigyi G. Different residues mediate recognition of 1-O-oleyl-lysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2006, 281:3398-3407.
35. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPAR gamma. J. Biol. Chem. 1998, 273:31108-31112.
36. Vanden Heuvel J.P., Thompson J.T., Frame S.R., Gillies P.J. Differential activation of nuclear receptors by perfluorinated fatty acid analogs and natural fatty acids: a comparison of human, mouse, and rat peroxisome proliferator-activated receptor-alpha, -beta, and -gamma, liver X receptor-beta, and retinoid X receptor-alpha. Toxicol. Sci. 2006, 92:476-489.
37. Waku T., Shiraki T., Oyama T., Maebara K., Nakamori R., Morikawa K. The nuclear receptor PPAR gamma individually responds to serotonin- and fatty acid-metabolites. EMBO J. 2010, 29:3395-3407.
38. Walters M.W., Bjork J.A., Wallace K.B. Perfluorooctanoic acid stimulated mitochondrial biogenesis and gene transcription in rats. Toxicology 2009, 264:10-15.
39. Weiss J.M., Andersson P.L., Lamoree M.H., Leonards P.E.G., van Leeuwen S.P.J., Hamers T. Competitive binding of poly- and perfluorinated compounds to the thyroid hormone transport protein transthyretin. Toxicol. Sci. 2009, 109:206-216.
40. White S.S., Fenton S.E., Hines E.P. Endocrine disrupting properties of perfluorooctanoic acid. J. Steroid Biochem. 2011, 127:16-26.
41. Wolf C.J., Schmid J.E., Lau C., Abbott B.D. Activation of mouse and human peroxisome proliferator-activated receptor-alpha (PPAR alpha) by perfluoroalkyl acids (PFAAs): further investigation of C4-C12 compounds. Reprod. Toxicol. 2012, 33:546-551.
42. Wolf D.C., Moore T., Abbott B.D., Rosen M.B., Das K.P., Zehr R.D., Lindstrom A.B., Strynar M.J., Lau C. Comparative hepatic effects of perfluorooctanoic acid and wy 14,643 in ppar-alpha knockout and wild-type mice. Toxicol. Pathol. 2008, 36:632-639.
43. Yang J.T., Wu C.S.C., Martinez H.M. Calculation of protein conformation from circular-dichroism. Methods Enzymol. 1986, 130:208-269.
44. Zhang L., Ren X.-M., Guo L.-H. Structure-based investigation on the interaction of perfluorinated compounds with human liver fatty acid binding protein. Environ. Sci. Technol. 2013, 47:11293-11301.
45. Zoete V., Grosdidier A., Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids 2007, 1771:915-925.